The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ostroumova O.D.

Russian Medical Academy for Continuous Professional Education

Shatalova N.A.

Russian Medical Academy for Continuous Professional Education

Kochetkov A.I.

Russian Medical Academy of Continuous Professional Education

Health Formula

Authors:

Ostroumova O.D., Shatalova N.A., Kochetkov A.I.

More about the authors

Journal: Non Nocere. New Therapeutic Journal. 2023;(9): 110‑117

Read: 581 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Ostroumova OD, Shatalova NA, Kochetkov AI. Health Formula. Non Nocere. New Therapeutic Journal. 2023;(9):110‑117. (In Russ.)

 
 
 
ЭндоКард
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Cognitive impairment in primary care physician practice: focus on patients with arterial hypertension.

Authors:

Ostroumova O.D.

Russian Medical Academy for Continuous Professional Education

Shatalova N.A.

Russian Medical Academy for Continuous Professional Education

Kochetkov A.I.

Russian Medical Academy of Continuous Professional Education

Close metadata

References:

  1. Muromtseva G.A., Kontsevaya A.V., Konstantinov V.V., et al. The prevalence of non-infectious diseases risk factors in russian population in 2012-2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014;13(6):4-11. (In Russ.) https://doi.org/10.15829/1728-8800-2014-6-4-11
  2. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-1913. https://doi.org/10.1016/s0140-6736(02)11911-8
  3. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens. 2000 Jan;13(1 Pt 2):3S-10S.  https://doi.org/10.1016/s0895-7061(99)00252-6
  4. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma β-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension. 2012 Apr;59(4):780-786.  https://doi.org/10.1161/HYPERTENSIONAHA.111.178962
  5. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L. Mild cognitive impairment: a concept in evolution. J Intern Med. 2014 Mar;275(3):214-228.  https://doi.org/10.1111/joim.12190
  6. Elias MF, Wolf PA, D’Agostino RB, Cobb J, White LR. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am J Epidemiol. 1993 Sep 15;138(6):353-364.  https://doi.org/10.1093/oxfordjournals.aje.a116868
  7. Iadecola C, Gottesman RF. Cerebrovascular Alterations in Alzheimer Disease. Circ Res. 2018 Aug 3;123(4):406-408.  https://doi.org/10.1161/CIRCRESAHA.118.313400
  8. Kobalava Z.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786
  9. Jessen F, Amariglio RE, Buckley RF, van der Flier WM, Han Y, Molinuevo JL, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020 Mar;19(3):271-278.  https://doi.org/10.1016/S1474-4422(19)30368-0
  10. McCollum L, Karlawish J. Cognitive Impairment Evaluation and Management. Med Clin North Am. 2020 Sep;104(5):807-825.  https://doi.org/10.1016/j.mcna.2020.06.007
  11. Beynon R, Sterne JA, Wilcock G, Likeman M, Harbord RM, Astin M, et al. Is MRI better than CT for detecting a vascular component to dementia? A systematic review and meta-analysis. BMC Neurol. 2012 Jun 6;12:33.  https://doi.org/10.1186/1471-2377-12-33
  12. Health Quality Ontario. The appropriate use of neuroimaging in the diagnostic work-up of dementia: an evidence-based analysis. Ont Health Technol Assess Ser. 2014;14(1):1-64. 
  13. Staffaroni AM, Elahi FM, McDermott D, Marton K, Karageorgiou E, Sacco S, et al. Neuroimaging in Dementia. Semin Neurol. 2017 Oct;37(5):510-537.  https://doi.org/10.1055/s-0037-1608808
  14. Živanović M, Aracki Trenkić A, Milošević V, Stojanov D, Mišić M, Radovanović M, Radovanović V. The role of magnetic resonance imaging in the diagnosis and prognosis of dementia. Biomol Biomed. 2023 Mar 16;23(2):209-224.  https://doi.org/10.17305/bjbms.2022.8085
  15. Whitwell JL. Progression of atrophy in Alzheimer’s disease and related disorders. Neurotox Res. 2010 Nov;18(3-4):339-346.  https://doi.org/10.1007/s12640-010-9175-1
  16. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-198.  https://doi.org/10.1016/0022-3956(75)90026-6
  17. MoCA COGNITION [Electronic resource]. Available at: https://mocacognition.com.Accessed:30September2023.
  18. Mormont E, Jamart J, Robaye L. Validity of the five-word test for the evaluation of verbal episodic memory and dementia in a memory clinic setting. J Geriatr Psychiatry Neurol. 2012 Jun;25(2):78-84.  https://doi.org/10.1177/0891988712445088
  19. Nishiwaki Y, Breeze E, Smeeth L, Bulpitt CJ, Peters R, Fletcher AE. Validity of the Clock-Drawing Test as a screening tool for cognitive impairment in the elderly. Am J Epidemiol. 2004 Oct 15;160(8):797-807.  https://doi.org/10.1093/aje/kwh288
  20. Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-1454. https://doi.org/10.1046/j.1532-5415.2003.51465.x
  21. Borkowski JG, Benton A, Spreen O. Word fluency and brain damage. Neuropsychologia. 1976;5:135-140. 
  22. Bogolepova AN, Vasenina EE, Gomzyakova NA, Gusev EI, Dudchenko NG, Emelin AYu, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(10-3):6-137. (In Russ.) https://doi.org/10.17116/jnevro20211211036
  23. Lin JS, O’Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: A systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013 Nov 5;159(9):601-612.  https://doi.org/10.7326/0003-4819-159-9-201311050-00730
  24. Chun CT, Seward K, Patterson A, Melton A, MacDonald-Wicks L. Evaluation of Available Cognitive Tools Used to Measure Mild Cognitive Decline: A Scoping Review. Nutrients. 2021 Nov 8;13(11):3974. https://doi.org/10.3390/nu13113974
  25. Bloniecki V, Ulfvarson J, Javanshiri K, Hagman G, Freund-Levi Y, Nordström A. The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort. J Prev Alzheimers Dis. 2023;10(2):207-211.  https://doi.org/10.14283/jpad.2023.9
  26. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment [published correction appears in J Am Geriatr Soc. 2019;67(9):1991]. J Am Geriatr Soc. 2005;53(4):695-699. 
  27. Zakharov V.V. Neuropsychological tests. Necessity and possibility of application. Consilium Medicum. 2011;13(2):98-106. 
  28. Zaidi KB, Rich JB, Sunderland KM, Binns MA, Truong L, McLaughlin PM, et al. Methods for Improving Screening for Vascular Cognitive Impairment Using the Montreal Cognitive Assessment. Can J Neurol Sci. 2020 Nov;47(6):756-763.  https://doi.org/10.1017/cjn.2020.121
  29. Kiely KM, Butterworth P, Watson N, Wooden M. The Symbol Digit Modalities Test: Normative data from a large nationally representative sample of Australians. Arch Clin Neuropsychol. 2014 Dec;29(8):767-775.  https://doi.org/10.1093/arclin/acu055
  30. Kaplan EF, Goodglass H, Weintraub S. The Boston Naming Test (2nd ed.). Lea & Febiger. Philadelphia, 1983. – 120 p. 
  31. Zec RF, Burkett NR, Markwell SJ, Larsen DL. Normative data stratified for age, education, and gender on the Boston Naming Test. Clin Neuropsychol. 2007 Jul;21(4):617-637.  https://doi.org/10.1080/13854040701339356
  32. Wechsler D.A. Standardized memory scale for clinical use. J. Psychol. 1945;19(1):87-95. 
  33. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology. 2000 Dec 12;55(11):1621-1626. https://doi.org/10.1212/wnl.55.11.1621
  34. Reitan RM. Validity of the Trail Making test as an indicator of organic brain damage. Percept. Mot. Skills. 1958;8:271-276. 
  35. Suddell S, Mahedy L, Skirrow C, Penton-Voak IS, Munafò MR, Wootton RE. Cognitive functioning in anxiety and depression: results from the ALSPAC cohort. R Soc Open Sci. 2023 Aug 9;10(8):221161. https://doi.org/10.1098/rsos.221161
  36. Mirza SS, Ikram MA, Bos D, Mihaescu R, Hofman A, Tiemeier H. Mild cognitive impairment and risk of depression and anxiety: A population-based study. Alzheimers Dement. 2017 Feb;13(2):130-139.  https://doi.org/10.1016/j.jalz.2016.06.2361
  37. Beauchet O, Launay CP, Annweiler C, Allali G. Hippocampal volume, early cognitive decline and gait variability: which association? Exp Gerontol. 2015 Jan;61:98-104.  https://doi.org/10.1016/j.exger.2014.11.002
  38. Allali G, Launay CP, Blumen HM, Callisaya ML, De Cock AM, Kressig RW, et al. Falls, Cognitive Impairment, and Gait Performance: Results From the GOOD Initiative. J Am Med Dir Assoc. 2017 Apr 1;18(4):335-340.  https://doi.org/10.1016/j.jamda.2016.10.008
  39. Laurent L, Koskas P, Estrada J, Sebbagh M, Lacaille S, Raynaud-Simon A, Lilamand M. Tinetti balance performance is associated with mortality in older adults with late-onset Parkinson’s disease: a longitudinal study. BMC Geriatr. 2023 Jan 30;23(1):54.  https://doi.org/10.1186/s12877-023-03776-7
  40. Kadykov A.S., Manvelov L.S. Tests and scales in neurology: a guide for doctors. - Moscow: MEDpress-Inform, 2015. - 224 p. 
  41. Moser M, Roccella EJ. The treatment of hypertension: a remarkable success story. J Clin Hypertens (Greenwich). 2013 Feb;15(2):88-91.  https://doi.org/10.1111/jch.12033
  42. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, et al. Impact of Hypertension on Cognitive Function: A Scientific Statement From the American Heart Association. Hypertension. 2016 Dec;68(6):e67–e94.  https://doi.org/10.1161/HYP.0000000000000053
  43. Zueva IB. Hypertension and cognitive impairments: Possible mechanisms of development, diagnosis, and approaches to therapy. Terapevticheskii Arkhiv. 2015;87(12):96-100. (In Russ.) https://doi.org/10.17116/terarkh2015871296-100
  44. Evdokimova AG, Kiparisova ES, Kovalenko EV, et al. Prevention and treatment of cognitive impairment in patients with hypertensive encephalopathy. Therapeutics. 2017;4(14):31-37. 
  45. Voronina TA. Mexidol: the spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2012;112(12):86-90. (In Russ.)
  46. Shchulkin AV, Yakusheva EN, Chernykh IV. A comparative study of mexidol and mexiprim pharmacokinetic parameters. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(11-2):40-43. (In Russ.)
  47. Kunel’skaya NL, Levina IuV, Yanyushkina ES, Ogorodnikov DS, Larionova EV. Possibility of application Mexidol for the treatment of patients suffering from sensorineural hearing loss and cerebrovascular insufficiency. Vestnik Oto-Rino-Laringologii. 2019;84(6):108-111. (In Russ.) https://doi.org/10.17116/otorino201984061108
  48. Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol® and Mexidol® FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Therapy. 2023;9(1):145-159.  https://doi.org/10.18565/therapy.2023.1.145-159
  49. Fedin AI, Zaharov VV, Tanashyan MM, Chukanova EI, Madzhidova EN, Shchepankevich LA, Ostroumova OD. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2021;121(11):7-16. (In Russ.) https://doi.org/10.17116/jnevro20211211117
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.